Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples